Drugs / methylcholine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00928252 | Jun 2009 → Jun 2016 | hormone-resistant prostate carcinoma | Queen's Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | methylcholine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00928252 ↗ |
| Modality | Diagnostic / imaging agent | “The study evaluates a diagnostic intervention” NCT00928252 ↗ |
| Route | Intravenous | “IV fluorine-18 labeled methylcholine before PET/CT” NCT00928252 ↗ |